Yale Study Finds Semaglutide Needs AgRP Neurons to Sustain 15-Day Weight Loss
Updated
Updated · ScienceAlert · Aug 15
Yale Study Finds Semaglutide Needs AgRP Neurons to Sustain 15-Day Weight Loss
3 articles · Updated · ScienceAlert · Aug 15
Summary
Female mice with disrupted AgRP “hunger neurons” regained semaglutide-linked weight loss within 15 days, even though they kept eating less during treatment.
The Yale team found the drug’s full effect depended on those neurons supporting a metabolic response—especially mobilizing stored fat—not just suppressing appetite.
Further tests showed blocking the fat-mobilization signaling pathway also weakened semaglutide’s weight-lowering effect, while prolonged treatment altered activity and connections in AgRP cells.
The result challenges a simpler view of GLP-1 drugs as appetite suppressants alone, but the researchers said the preclinical mouse data—strongest in females—should not guide human use yet.
If confirmed in people, the mechanism could help explain why patients respond differently to semaglutide and inform more effective obesity treatments.